Granted Patent B2

US 9,675,668 · App. 14/105,208 · Granted Jun 13, 2017

Inventors: Stephane Bancel (Cambridge, MA); Tirtha Chakraborty (Medford, MA); Antonin de Fougerolles (Waterloo, BE); Susan Whoriskey (Belmont, MA); Ron Weiss (Newton, MA)

Assignee: Moderna Therapeutics, Inc.

A61K38/177A61K9/1271A61K31/7115A61K38/17A61K38/45A61K48/005A61K48/0033A61K48/0066C07K14/005C07K14/435C07K14/47C07K14/4705C07K14/4713C07K14/485C07K14/505C07K14/535C07K14/62C07K14/705C12N9/1051C12N9/16C12N9/2402C12N9/2445C12N9/6451C12N9/88C12N9/93C12N15/11C12N15/52C12N15/85C12N15/87C12P13/04C12P21/00C12Y603/02019A61K38/00

Abstract

Claims (14)

1. An mRNA encoding SEQ ID NO: 10767, wherein said mRNA comprises a coding region having at least 85% identity to SEQ ID NO: 34731.

2. The mRNA of claim 1 , wherein the mRNA comprises at least one untranslated region 5′ relative to the coding region and at least one untranslated region 3′ relative to the coding region.

3. The mRNA of claim 2 , wherein the 5′ untranslated region is heterologous to the coding region of the mRNA.

4. The mRNA of claim 2 , wherein the 3′ untranslated region is heterologous to the coding region of the mRNA.

5. The mRNA of claim 2 , wherein the 5′ untranslated region and the 3′ untranslated region are heterologous to the coding region of the mRNA.

6. The mRNA of claim 2 , wherein the mRNA comprises at least two stop codons.

7. A pharmaceutical composition comprising the mRNA of claim 1 and a pharmaceutically acceptable excipient.

8. The pharmaceutical composition of claim 7 wherein the pharmaceutically acceptable excipient is selected from a solvent, aqueous solvent, non-aqueous solvent, dispersion media, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, lipid, lipidoids liposome, lipid nanoparticle, core-shell nanoparticles, polymer, lipoplex, peptide, protein, cell, hyaluronidase, and mixtures thereof.

9. A method of producing a protein of interest in a cell, tissue or organism comprising contacting said cell, tissue or organism with the mRNA of claim 1 .

10. The method of claim 9 , wherein the mRNA comprises at least one untranslated region 5′ relative to the coding region and at least one untranslated region 3′ relative to the coding region.

11. The method of claim 10 , wherein the 5′ untranslated region is heterologous to the coding region of the mRNA.

12. The method of claim 10 , wherein the 3′ untranslated region is heterologous to the coding region of the mRNA.

13. The method of claim 10 , wherein the 5′ untranslated region and the 3′ untranslated region are heterologous to the coding region of the mRNA.

14. The method of claim 10 , wherein the mRNA comprises at least two stop codons.

Assignments (3)

Continuity (53)